Nasdaq nmra.

Research Neumora Therapeutics' (Nasdaq:NMRA) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, ... It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; ...

Nasdaq nmra. Things To Know About Nasdaq nmra.

The latest price target for Neumora Therapeutics ( NASDAQ: NMRA) was reported by JP Morgan on Tuesday, October 10, 2023. The analyst firm set a price target for 21.00 expecting NMRA to rise to ...Progressing NMRA-511 and NMRA-266 toward near-term clinical milestones and advancing multiple preclinical neuropsychiatric and neurodegeneration programs. ... Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception ...Neumora Therapeutics Inc (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics recently initiated a Phase 1 single ascending dose / multiple ascending dose study of ...WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) major shareholder Arch Venture Partners Xii, Llc bought 3,357 shares of the company’s stock in a transaction on Tuesday, November 14th.Neumora Therapeutics is a biotech company located in Massachusetts, United States, which is part of the Healthcare sector, and is traded under the ticker NMRA on the NASDAQ exchange. Neumora Therapeutics stock last closed at $11.69 , down 1.35% from the previous day, and has decreased N/A in one year.Nov 8, 2023 · Within the last quarter, Neumora Therapeutics (NASDAQ:NMRA) has observed the following analyst ratings: According to 6 analyst offering 12-month price targets in the last 3 months, Neumora ...

NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and …

Oct 10, 2023 · In addition, NMRA-266 (M4R PAM), another drug in development for the treatment of schizophrenia, is viewed as a de-risked asset due to the large market and low entry barriers for this disease. Neumora Therapeutics (NASDAQ:NMRA) shares are up over 15% this morning. 10 Top Losers Vivos Therapeutics (NASDAQ: VVOS ) stock is plummeting nearly 34% after a massive rally yesterday on FDA news .A Quick Take On Neumora Therapeutics. Neumora Therapeutics, Inc. ( NASDAQ: NMRA) has filed proposed terms to raise $250 million from the sale of its common stock in an IPO, according to an amended ...WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided a general business update.

Nasdaq | NMRA U.S.: Nasdaq Neumora Therapeutics Inc. Watch list NEW Set a price target alert After Hours Last Updated: Oct 4, 2023 7:35 p.m. EDT Delayed quote $ 12.27 0.36 3.02% After Hours...

WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug ...

Research Neumora Therapeutics' (Nasdaq:NMRA) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance ...Nov 27, 2023 · NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. Neumora Therapeutics (NASDAQ:NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer opened at $16.50 after being priced at $17 per ...Neumora Therapeutics Inc. began trading on the Nasdaq Friday around 12:30 p.m. under the ticker symbol "NMRA." The Watertown startup sold 14.7 million shares at $17 each, the midpoint of its range.Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) major shareholder Arch Venture Partners Xii, Llc bought 3,357 shares of the company’s stock in a transaction on Tuesday, November 14th.

NMRA Most Active Options. Most Active LEAPS Data is currently not available. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ...Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.View live price data for NMRA (Neumora Therapeutics, Inc.) on TrendSpider to track real-time price action, options flow, and news on this asset and hundreds more. Dark Light. Search Ctrl + K. Login Try full version. Smart Watchlists. NMRA. NMRA. Neumora Therapeutics, Inc. 10.02 USD +0.38 (+3.94%) Last updated Oct 13, 21:00 UTC. …Nov 22, 2023 · 6 Wall Street analysts have issued 12-month price objectives for Neumora Therapeutics' stock. Their NMRA share price targets range from $18.00 to $26.00. On average, they predict the company's stock price to reach $22.67 in the next year. This suggests a possible upside of 90.3% from the stock's current price. Neumora Therapeutics, Inc. (NASDAQ: NMRA) is a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Neumora is redefining neuroscience research and development with a data-driven precision neuroscience platform to cut through brain disease heterogeneity ...10 Okt 2023 ... Market Conditions: The broader stock market experienced a mixed situation on October 2, 2023. This can be attributed to concerns such as ...

Nov 24, 2023 · A high-level overview of Neumora Therapeutics, Inc. (NMRA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Neumora Therapeutics (NASDAQ:NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer opened at $16.50 after being priced at $17 per ...

Sep 15, 2023 · Find the latest Earnings Report Date for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com. ... (NASDAQ: NMRA), and Syllable Life Sciences (acquired by Neumora). Portfolio. Atalanta Therapeutics. Atalanta Therapeutics is a biotechnology company pioneering ...Nov 1, 2023 · Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ... A high-level overview of Neumora Therapeutics, Inc. (NMRA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …Oct 14, 2023 · Neumora Therapeutics Inc. (NASDAQ: NMRA) grossed $250.1 million in a September initial public offering that was due in part to a drug pipeline that includes an experimental schizophrenia drug that ... Neumora hopes to list its shares on Nasdaq under the symbol NMRA. JP Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets and William Blair are serving a joint bookrunners.It plans to list on the Nasdaq under the ticker symbol "NMRA." J.P. Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets and William Blair are backing the listing. Neumora ...Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Neumora Therapeutics, Inc. Common Stock (NMRA) Pre-Market Stock Quotes - Nasdaq ...

Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.

View real-time NMRA stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...

On October 10, 2023, Geoff Meacham, an analyst at Bank of America Securities, commenced coverage on Neumora Therapeutics (NASDAQ:NMRA) by Analyst Coverage and Price Targets for Neumora Therapeutics - Best StocksStock Quote. NASDAQ GS: NMRA. $12.33. Dec 1, 2023 4:00 PM EST. Change. +0.08 (+0.65%). Volume. 232,481. Today's Open. $12.24. Previous Close. $12.25. Today's ...Get the latest Neumora Therapeutics, Inc NMRA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... NASDAQ data is at least 15 minutes delayed.Find the latest Financials data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.Christoph Burgstedt/iStock via Getty Images. Company logo. I started a long position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) last week with a 4.2% portfolio allocation.This recent central ...WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...US6409791000. Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action ...Atomera Inc (NASDAQ:ATOM)’s traded shares stood at 0.16 million during the last session, with the company’s beta value hitting 1.45. At the close of trading, the stock’s price was $6.97, to imply an increase of 0.29% or $0.02 in intraday trading. The ATOM share’s 52-week high remains $10.72 ...Sep 26, 2023 · Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending Tickers bar NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ...Fiscal Q3 2023 ended 9/30/23. Get the latest Neumora Therapeutics Inc (NMRA) real-time quote, historical performance, charts, and other financial information to help you make more informed...NMRA-266 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype, a clinically validated target for the treatment of schizophrenia. Neumora exclusively licensed ...

View Neumora Therapeutics, Inc NMRA investment & stock information. Get the latest Neumora Therapeutics, Inc NMRA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.6 Wall Street analysts have issued 12-month price objectives for Neumora Therapeutics' stock. Their NMRA share price targets range from $18.00 to $26.00. On …The latest price target for . Neumora Therapeutics (NASDAQ: NMRA) was reported by JP Morgan on Tuesday, October 10, 2023.The analyst firm set a price target for 21.00 expecting NMRA to rise to ...Instagram:https://instagram. nasdaq ttd financialsbj's wholesale club stockhow much are 1921 silver dollars worthprtc us The Watertown, MA-based Neumora Therapeutics ( NASDAQ: NMRA ), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its ...Amneal Pharmaceuticals Stock (NYSE: AMRX) stock price, news, charts, stock research, profile. top retirement mutual fundsbest day trading companies Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares rose 33.4% to $0.2326 in pre-market trading after falling 8% on Wednesday. Robert Davidow reported a14.5 % passive stake in Avenue Therapeutics in a ... under 500 credit score home loan (NASDAQ: NMRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.21%. What is NMRA's Price Target? According to 5 Wall Street analyst s that have issued a 1 year NMRA price target, the average NMRA price target is $22.00 , with the highest NMRA stock price forecast at $26.00 and the lowest NMRA stock ... Oct 18, 2023 · Christoph Burgstedt/iStock via Getty Images. Company logo. I started a long position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) last week with a 4.2% portfolio allocation.This recent central ...